LAS VEGAS, NEVADA – A new canine oncology therapy will be launched at the annual Veterinary Cancer Society conference taking place in Las Vegas, Nevada, from October 18 through 21.
Bioniche Life Sciences, Inc., is the biopharmaceutical company behind the launch of Immunocidin, touted as the company’s proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer (Urocidin) was derived. The drug will be used for intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.
Regulatory approval for the drug has been received in the United States and Canada and is now available in the U.S., with expected availability soon in Canada.
Andrew Grant, President, Bioniche Animal Health (global), stated, “We are excited to be entering the canine oncology market in North America. We believe there is a tremendous opportunity for a product like ImmunocidinTM that does not require special handling and can be used by veterinarians in their own clinics, either alone or in combination with other therapies.”
According to a release by Bioniche Life Sciences, canine cancer is the leading disease-related cause of death in dogs and approximately one in four dogs die of cancer. The second oncology product that will be released is Oncocidin.
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products across the globe. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington.
For more information, visit the official website at www.Bioniche.com.